[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President & Executive Board Member", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 33.005, "open": 33.42, "dayLow": 32.37, "dayHigh": 37.07, "regularMarketPreviousClose": 33.005, "regularMarketOpen": 33.42, "regularMarketDayLow": 32.37, "regularMarketDayHigh": 37.07, "payoutRatio": 0.0, "beta": 0.027, "forwardPE": -19.603174, "volume": 2094562, "regularMarketVolume": 2094562, "averageVolume": 922851, "averageVolume10days": 1216140, "averageDailyVolume10Day": 1216140, "bid": 36.39, "ask": 37.08, "bidSize": 10, "askSize": 10, "marketCap": 4172884224, "fiftyTwoWeekLow": 14.06, "fiftyTwoWeekHigh": 37.07, "allTimeHigh": 37.07, "allTimeLow": 5.633, "priceToSalesTrailing12Months": 65.195206, "fiftyDayAverage": 26.3113, "twoHundredDayAverage": 22.059925, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3434050304, "profitMargins": -2.58905, "floatShares": 56140781, "sharesOutstanding": 112628458, "sharesShort": 7640225, "sharesShortPriorMonth": 7497579, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.0678, "heldPercentInsiders": 0.00385, "heldPercentInstitutions": 1.0582399, "shortRatio": 7.58, "shortPercentOfFloat": 0.0809, "impliedSharesOutstanding": 112628458, "bookValue": 6.919, "priceToBook": 5.35482, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -165715008, "trailingEps": -1.59, "forwardEps": -1.89, "enterpriseToRevenue": 53.652, "enterpriseToEbitda": -19.894, "52WeekChange": 0.93371606, "SandP52WeekChange": 0.118204355, "quoteType": "EQUITY", "currentPrice": 37.05, "targetHighPrice": 44.838337, "targetLowPrice": 26.984184, "targetMeanPrice": 40.514656, "targetMedianPrice": 41.470695, "recommendationMean": 1.38462, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 739161984, "totalCashPerShare": 6.563, "ebitda": -172616000, "totalDebt": 328000, "quickRatio": 20.785, "currentRatio": 21.085, "totalRevenue": 64006000, "debtToEquity": 0.042, "revenuePerShare": 0.597, "returnOnAssets": -0.17118, "returnOnEquity": -0.28426, "grossProfits": 64006000, "freeCashflow": -85028000, "operatingCashflow": -124122000, "revenueGrowth": 7.401, "grossMargins": 1.0, "ebitdaMargins": -2.69687, "operatingMargins": -1.86132, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1760140798, "regularMarketTime": 1760126400, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 12.2557, "regularMarketPrice": 37.05, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "shortName": "NewAmsterdam Pharma Company N.V", "marketState": "CLOSED", "earningsTimestamp": 1754539200, "earningsTimestampStart": 1762345800, "earningsTimestampEnd": 1762345800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.59, "epsForward": -1.89, "epsCurrentYear": -1.19567, "priceEpsCurrentYear": -30.98681, "fiftyDayAverageChange": 10.738699, "fiftyDayAverageChangePercent": 0.40814018, "twoHundredDayAverageChange": 14.990074, "twoHundredDayAverageChangePercent": 0.6795161, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-10-10", "averageAnalystRating": "1.4 - Strong Buy", "postMarketChangePercent": -0.134951, "postMarketPrice": 37.0, "postMarketChange": -0.0499992, "regularMarketChange": 4.045, "regularMarketDayRange": "32.37 - 37.07", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 922851, "fiftyTwoWeekLowChange": 22.989998, "fiftyTwoWeekLowChangePercent": 1.6351349, "fiftyTwoWeekRange": "14.06 - 37.07", "fiftyTwoWeekHighChange": -0.020000458, "fiftyTwoWeekHighChangePercent": -0.00053953216, "fiftyTwoWeekChangePercent": 93.371605, "longName": "NewAmsterdam Pharma Company N.V.", "cryptoTradeable": false, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-10-11"}]